Bladder Cancer & Urothelial Carcinoma Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.
Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.View More
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.View More
Petros Grivas, MD, PhD, discusses interim findings from the phase 3 JAVELIN Bladder 100 clinical trial presented at the virtual 2020 ASCO Annual Meeting.View More
Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.View More
Enfortumab vedotin monotherapy has demonstrated meaningful and durable responses in patients with metastatic urothelial cancer.View More